Ignite Creation Date:
2024-05-06 @ 12:46 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01654081
Status:
WITHDRAWN
Last Update Posted:
2014-05-30
First Post:
2012-07-27
Brief Title:
A Protocol of Irinotecan for Carcinoma of the Lung
Sponsor:
Susanne Arnold
Organization:
University of Kentucky
Study Overview
Official Title:
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status:
WITHDRAWN
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this trial is to demonstrate the potential clinical benefit of irinotecan chemotherapy in patients with a specific NSCLC phenotype ISG15-positive The use of irinotecan in subjects with ISG15-positive NSCLC will be associated with an improved rate of clinical benefit objective response disease stability and time to progression compared to historical controls that were not previously selected for ISG-15 expression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None